^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NSP-1047

    i
    Other names: NSP-1047, NSP1047, NSP 1047
    Associations

    News

    Trials
    Company:
    Novostar Pharma
    Drug class:
    MKNK inhibitor, MKNK1 inhibitor, MKNK2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over2years
    Antitumor activity of a potent MNK inhibitor NSP-1047 in acute myeloid leukemia (AACR 2023)
    NSP-1047 potently inhibits the expression of multiple immune checkpoint proteins, including PD-1, Tim-3, and Lag-3, and it also inhibits the secretion of several inflammatory cytokines, such as IL-6, IL-8 and IL-10. NSP-1047 displays excellent ADME and pharmacokinetic properties, and demonstrates potent in vivo antitumor activity in acute myeloid leukemia animal models with tumor regression.
    PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • IL6 (Interleukin 6) • LAG3 (Lymphocyte Activating 3) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • IL10 (Interleukin 10)
    |
    NSP-1047